15 (R) -Lipoxin A4

15 (R) -Lipoxin A4 (15-epi-LXA4) is a STAT-6 activator and a lipid-derived lipoxin-type specialized pro-resolving mediator (SPM) that plays a role in promoting inflammation resolution and regulating immune cell function. 15 (R) -Lipoxin A4 can improve the phagocytic function of microglia and exhibits anti-inflammatory activity. In Alzheimer's disease (AD) mouse models, 15 (R) -Lipoxin A4 improves AD-like pathology. 15 (R) -Lipoxin A4 holds potential for use in inflammation and neurodegenerative disease research[1].

Product Specifications

CAS Number

[171030-11-8]

Product Name Alternative

15-epi-LXA4

UNSPSC

12352211

Hazard Statement

H225, H319

Target

STAT

Type

Natural Products

Related Pathways

JAK/STAT Signaling; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/15-r-lipoxin-a4.html

Concentration

283.71 μM * 250 μL in Ethanol

Purity

98.3

Smiles

CCCCC[C@@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](O)CCCC(O)=O

Molecular Formula

C20H32O5

Molecular Weight

352.47

Precautions

H225, H319

References & Citations

[1]Lee JY, et al. Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease. Nat Commun. 2018 Apr 16;9 (1) :1479.|[2]Dakin S G, et al. 15-Epi-LXA4 and MaR1 counter inflammation in stromal cells from patients with Achilles tendinopathy and rupture[J]. The FASEB Journal, 2019, 33 (7) : 8043.